Both Adderall and Strattera Can Be Continued During Pregnancy When Needed for Functioning
Recent high-quality evidence demonstrates that both amphetamines (Adderall) and atomoxetine (Strattera) do not increase the risk of major congenital malformations or long-term neurodevelopmental disorders in offspring, and treatment should not be stopped if required for daily functioning. 1, 2
Key Safety Evidence
Long-Term Neurodevelopmental Outcomes (Most Important for Quality of Life)
A 2025 population-based cohort study and meta-analysis provides the most reassuring evidence: maternal ADHD medication during pregnancy does not increase the risk of neurodevelopmental disorders, impairments in vision or hearing, epilepsy, seizures, or growth impairment in offspring 1. This applies to both amphetamines and atomoxetine.
Congenital Malformations
Amphetamines (Adderall): Do not appear to be associated with major congenital malformations or cardiac malformations 2. One study suggested possible increased risk of gastroschisis (aOR 3.0), but this has a small absolute risk given the rarity of the condition (0.05% population prevalence) and confounding by indication cannot be ruled out 2.
Atomoxetine (Strattera): Does not appear to be associated with major congenital malformations, including cardiac malformations 2. A 2023 multinational study of nearly 1,000 first-trimester exposures found no increased risk (adjusted PR 0.99,95% CI 0.74-1.34) 3.
Obstetrical Complications
Both medications carry some potential risks that require monitoring:
Amphetamines:
- Possible small increased risk of preeclampsia (aRR 1.29,95% CI 1.11-1.49) 2
- Possible small increased risk of preterm birth when continued in second half of pregnancy (aRR 1.30,95% CI 1.10-1.55) 2
- Possible increased risk of poor neonatal adaptation (23.6% vs 13.5%, P=0.05) 2
Atomoxetine:
- Possible increased risk of spontaneous abortion, though confounding by indication cannot be ruled out 2
- May modestly increase preterm birth risk with early pregnancy use (≥2 prescriptions: aRR 1.29,95% CI 1.08-1.53) 4
Clinical Decision Algorithm
For Patients Already on Medication
If well-controlled on current medication (either Adderall or Strattera): Continue the medication 1. There is no compelling reason to switch based on safety concerns regarding long-term outcomes.
If considering discontinuation: Only attempt if it will not severely impact daily functioning 2. Untreated ADHD during pregnancy can lead to worse mental health outcomes, increased risk of spontaneous abortion, and preterm birth 2.
For New Users During Pregnancy
Methylphenidate appears to be the 'safest' choice for new users, as it is the most thoroughly investigated ADHD medication 1. However, if methylphenidate is not an option:
- Both amphetamines and atomoxetine are reasonable alternatives
- The sample sizes for these medications are relatively small, requiring more data for confirmation 1
Monitoring Requirements During Pregnancy
Essential monitoring includes:
- Fetal growth assessments
- Blood pressure checks for preeclampsia
- Ensure appropriate maternal weight gain
- Monitor for signs of preterm labor, especially in late pregnancy 2
Important Caveats
Confounding by Indication
Critical pitfall: Much of the observed risk may be attributable to ADHD itself rather than the medication 2. Women with ADHD who stopped medication during pregnancy had significant increases in depressive symptoms despite remaining on antidepressants 2.
Dose Considerations
- Use the lowest effective dose 2
- Consider intermittent use on an as-needed basis to maximize functioning while reducing fetal exposure 2
- This strategy is particularly feasible with stimulants given their rapid onset of action
FDA Labeling
The Strattera (atomoxetine) FDA label states it "should not be used during pregnancy unless the potential benefit justifies the potential risk to the fetus" 5. However, this conservative language predates the robust 2024-2025 guideline evidence showing reassuring safety data.
Breastfeeding Considerations
- Amphetamines: Hale lactation risk category L3. Limited data suggest breastfeeding does not adversely affect infants, though monitoring for irritability, insomnia, and feeding difficulty is recommended 2
- Atomoxetine: Caution advised due to lack of published studies. Based on pharmacokinetics (low molecular weight, long half-life), it will likely be present in human milk 2
Bottom Line
The consensus from 2024 American Journal of Obstetrics and Gynecology guidelines is clear: the magnitude of documented risks is very low, and treatment with medications should not be stopped if required for daily functioning 2. The risks of untreated ADHD during pregnancy—including impaired functioning, increased depression, spontaneous abortion, and preterm birth—must be weighed against the modest and uncertain medication risks in a shared decision-making process.